<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Mediators Inflamm</journal-id>
      <journal-id journal-id-type="iso-abbrev">Mediators Inflamm</journal-id>
      <journal-id journal-id-type="publisher-id">MI</journal-id>
      <journal-title-group>
        <journal-title>Mediators of Inflammation</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0962-9351</issn>
      <issn pub-type="epub">1466-1861</issn>
      <publisher>
        <publisher-name>Hindawi Publishing Corporation</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25922564</article-id>
      <article-id pub-id-type="pmc">4398911</article-id>
      <article-id pub-id-type="doi">10.1155/2015/792173</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Efficacy of Anakinra for Various Types of Crystal-Induced Arthritis in Complex Hospitalized Patients: A Case Series and Review of the Literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Aouba</surname>
            <given-names>A.</given-names>
          </name>
          <xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
          <xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Deshayes</surname>
            <given-names>S.</given-names>
          </name>
          <xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Frenzel</surname>
            <given-names>L.</given-names>
          </name>
          <xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Decottignies</surname>
            <given-names>A.</given-names>
          </name>
          <xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pressiat</surname>
            <given-names>C.</given-names>
          </name>
          <xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bienvenu</surname>
            <given-names>B.</given-names>
          </name>
          <xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Boue</surname>
            <given-names>F.</given-names>
          </name>
          <xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Damaj</surname>
            <given-names>G.</given-names>
          </name>
          <xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hermine</surname>
            <given-names>O.</given-names>
          </name>
          <xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Georgin-Lavialle</surname>
            <given-names>S.</given-names>
          </name>
          <xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="I1"><sup>1</sup>Department of Internal Medicine, CHU de Caen, Universit&#xE9; de Caen, Basse Normandie, avenue de la C&#xF4;te de Nacre, Caen, France</aff>
      <aff id="I2"><sup>2</sup>Department of Haematology, H&#xF4;pital Necker-Enfants Malades, 149 rue de Sevres, 75015 Paris, France</aff>
      <aff id="I3"><sup>3</sup>Department of Pharmacy, H&#xF4;pital Antoine B&#xE9;cl&#xE8;re, 157 rue de la Porte de Trivaux, 92141 Clamart Cedex, France</aff>
      <aff id="I4"><sup>4</sup>Department Haematology, CHU de Caen, Universit&#xE9; de Caen, Basse Normandie, avenue de la C&#xF4;te de Nacre, Caen, France</aff>
      <aff id="I5"><sup>5</sup>Department of Internal Medicine, H&#xF4;pital Tenon, Universit&#xE9; Paris 6 Pierre et Marie Curie, DHU I2B, 4 rue de la Chine, 75020 Paris, France</aff>
      <author-notes>
        <corresp id="cor1">*A. Aouba: <email>achille.aouba@gmail.com</email></corresp>
        <fn fn-type="other">
          <p>Academic Editor: Luca Cantarini</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>26</day>
        <month>3</month>
        <year>2015</year>
      </pub-date>
      <volume>2015</volume>
      <elocation-id>792173</elocation-id>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>1</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>12</day>
          <month>3</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>12</day>
          <month>3</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2015 A. Aouba et al.</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access">
          <license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>
<italic>Background</italic>. There are few data on anakinra use after failure of conventional medications for crystal-induced peripheral arthritis and/or crowned dens syndrome among complex hospitalized patients. <italic>Methods</italic>. We retrospectively analyzed the outcome of six patients affected with subacute crystal-induced arthritis who had received anakinra in second or third line therapy, including three patients with crowned dens syndrome and three others with gouty arthritis. Patients' comorbidities, reasons for anakinra use and associated drugs, and outcomes were recorded. <italic>Results</italic>. All patients presented with elevated inflammatory syndrome, systemic symptoms with poly/oligoarthritis. Except for absolute contraindications, all patients were previously treated with full or decreased dose of NSAID, colchicine, and/or glucocorticoids, with unsatisfactory response. All three gouty patients exhibited complete responses in all acute involvements under anakinra within 3 to 5 days, including one of them who needed the reintroduction of colchicine treatment that was previously unsuccessful. Crowned dens syndrome patients, including two with pseudogout and one with subacute hydroxyapatite deposition disease, needed 9 to 11 days to achieve complete response. Tolerance to anakinra was good. <italic>Conclusion</italic>. In case series of complex hospitalized patients, anakinra showed good activity in crowned dens syndrome and associated crystal-induced peripheral arthritis, with longer treatment duration than in gouty arthritis.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>1. Introduction</title>
      <p>The number of therapeutic drugs used to treat crystal-induced arthritis (CRIA) is relatively limited, relying on colchicine, nonsteroidal anti-inflammatory drugs, and corticosteroids. These drugs may have significant and severe side-effects or may be contraindicated and therefore cannot always be used at an optimal dosage especially among elderly patients. Thus, other therapeutic options are often required in clinical practice.</p>
      <p>Recently, several publications have focused on the rationale and efficacy of the interleukin-1 blockade mainly in gout [<xref rid="B1" ref-type="bibr">1</xref>&#x2013;<xref rid="B4" ref-type="bibr">4</xref>] and sparsely in pseudogout [<xref rid="B5" ref-type="bibr">5</xref>&#x2013;<xref rid="B7" ref-type="bibr">7</xref>]. No clear outcome parameters concerning notably the treatment duration of anakinra are defined. Otherwise, there is no report on the use of anakinra in the acute inflammatory manifestations of hydroxyapatite deposition disease (HADD) and notably in crowned dens syndrome, which is a clinical form that this latter shares with pseudogout. Both diagnosis and management of crowned dens syndrome can be challenging, and the control of the disease requires sometimes the combination of several drugs, with increased risk of toxicity especially in older patients.</p>
      <p>Herein, we report on the successful use of anakinra in the context of resistance or contraindications to conventional drugs, in six complex hospitalized elderly patients with crowned dens syndrome and associated crystal-induced peripheral arthritis (<italic>n</italic> = 3) and gouty polyarthritis on the other hand (<italic>n</italic> = 3).</p>
    </sec>
    <sec id="sec2">
      <title>2. Patients and Methods</title>
      <p>We retrospectively collected data from six adult patients who had received off-label anakinra (Kineret 100&#x2009;mg/day; subcutaneous injection) for CRIA (gout, pseudogout, or HADD) between January 2012 and March 2013. All patients included in this study were hospitalized or referred to the department of internal medicine. Approvals from institutional medical-pharmaceutical committee and review board were obtained for this study, and the patients' consent was obtained after providing them with information about anakinra.</p>
      <p>The diagnosis of gout was based on the presence of monosodium urate (MSU) crystals in synovial fluid, the presence of tophus, or the presence of at least six of the twelve other crystal-induced types of arthritis referred to in the criteria of the American College of Rheumatology [<xref rid="B18" ref-type="bibr">8</xref>]. The diagnosis of other types of CRIA was based on the same scheme, except for the characteristic signs of gout, including hydroxyapatite crystals for HADD or calcium pyrophosphate (CPP) crystals for pseudogout.</p>
      <p>In the setting of complex hospitalized patients, diagnosis of an attack of CRIA was based on the presence of compatible clinical signs, significant increase in C-reactive protein levels (CRP; normal &lt; 5&#x2009;mg/L) to at least 15&#x2009;mg/L, and associated typical imaging. Some differential diagnoses were ruled out by performing minimal autoimmune (antinuclear factor, anti-DNA, rheumatoid factor, anti-CCP, and ANCA antibodies) and routine microbiological exams. Serum uric acid levels were assessed (&gt;6.0&#x2009;mg/dL in women) also taking account of creatinine level. None of our six patients had a medical history or other clinical manifestations that evoked an inherited autoinflammatory syndrome.</p>
      <p>For an attack of CRIA, colchicine was given to patients 1 and 6, at 1&#x2009;mg/three times a day, on days 1 and 2; then 1&#x2009;mg twice daily, on days 3 and 4; and then 1&#x2009;mg a day on days 5 and 6. Reduced doses, for best tolerance with similar efficacy [<xref rid="B2" ref-type="bibr">2</xref>], were given to patients 2 and 4, whereas this drug was contraindicated in patients 3 and 5 (<xref ref-type="table" rid="tab1">Table 1</xref>). Long-term prophylaxis was given to patients who had exhibited previous recurrent attacks of polyarthritis with respect to renal function [<xref rid="B2" ref-type="bibr">2</xref>]. The nonsteroidal anti-inflammatory drugs that were routinely used were indomethacin (orally, 25&#x2009;mg, 3-4 times daily) or ketoprofen (100&#x2009;mg twice daily, orally and/or intravenously) given for 10&#x2013;14 days; doses were reduced by 30% for elderly patients and those at risk of renal damage with close creatinine monitoring. Prednisone was given at 0.5&#x2009;mg/kg/day (max. 40&#x2009;mg/day) for 15 days. Anakinra therapy was maintained until there was both a complete clinical response and normalization of CRP level. Treatment with anakinra was stopped by day 6 in the absence of any clinical improvement and no reduction in CRP level, which was monitored every 48&#x2013;72&#x2009;h.</p>
    </sec>
    <sec id="sec3">
      <title>3. Results</title>
      <sec id="sec3.1">
        <title>3.1. Main Features of the Patients</title>
        <p>Six patients were included in the study: three patients with crowned dens syndrome and associated acute/subacute crystal-induced peripheral arthritis (patients 1, 2, and 3; <xref ref-type="table" rid="tab1">Table 1</xref>; <xref ref-type="fig" rid="fig1">Figure 1</xref>) and three other with gout (patients 4, 5, and 6; <xref ref-type="table" rid="tab1">Table 1</xref>). They were two men and four women with a mean age of 72 years, ranging from 65 to 88. Most of them displayed comorbidities such as arterial hypertension (<italic>n</italic> = 4), hypothyroidism (<italic>n</italic> = 2), chronic kidney disease (<italic>n</italic> = 2), obesity (<italic>n</italic> = 1), diabetes (<italic>n</italic> = 1), and chronic hematological malignancies (MGUS: <italic>n</italic> = 1, prolymphocytic leukemia: <italic>n</italic> = 1, and polycythemia vera: <italic>n</italic> = 1). All patients exhibited low grade fever, alteration of the general status, and marked and/or persistent increased CRP levels over 3 weeks (<xref ref-type="table" rid="tab1">Table 1</xref>).</p>
        <p>Patients with crowned dens syndrome were more likely aged females (three women with mean age of 79 years) compared to gouty patients (two men, one woman with mean age of 69.6 years). For the three patients with crowned dens syndrome, the diagnosis was retained on clinical signs, namely, fever, multidirectional neck stiffness and pain, exclusion of meningitis with lumbar picture in two, and compatible features of neck CT-scan without any criteria for vertebral or soft-tissue infectious or tumoral process (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The diagnosis of crowned dens syndrome was moreover based on concomitant peripheral joint involvements criteria (<xref ref-type="table" rid="tab1">Table 1</xref>). Two patients had, respectively, a history of pseudogout and HADD diagnosed on typical crystal finding on joint puncture and compatible X-ray features. The latter exhibited calcium pyrophosphate crystals on knee joint puncture and iconographic pictures of pseudogout location, but also thick arciform calcification of the retrodens ligament on cervical CT-scan and HADD features on scapular MRI (Figures <xref ref-type="fig" rid="fig1">1(c)</xref>(A) and <xref ref-type="fig" rid="fig1">1(c)</xref>(B)).</p>
        <p>Among the three gouty patients, two were treated, respectively, with hydroxyurea and allopurinol for polycythemia vera and with pentostatin for a prolymphocytic leukemia without exhibiting criteria for tumor lysis syndrome; the latter exhibited severe chronic renal insufficiency related to gouty nephropathy.</p>
        <p>The localization of arthritis was different in the two groups: gouty patients presented symmetrical large and small joints arthritis whereas patients with crowned dens syndrome displayed by definition a periodontoid arthritis and often asymmetrical shoulder and/or wrist involvements.</p>
      </sec>
      <sec id="sec3.2">
        <title>3.2. Anakinra Efficacy among Patients with Crowned Dens Syndrome and Gout</title>
        <p>Indication for anakinra was mostly similar for both groups, including failure or contraindications to colchicine and/or nonsteroidal anti-inflammatory drugs or corticosteroids, especially for the associated comorbidities.</p>
        <p>Complete remission, defined both clinically and biologically with the normalization of CRP level (<xref ref-type="fig" rid="fig2">Figure 2</xref>), was obtained in all three gouty patients, whereas for the crowned dens syndrome group only two of three patients underwent complete remission with only anakinra. In the crowned dens syndrome group (patients 1, 2, and 3; <xref ref-type="table" rid="tab1">Table 1</xref>), 9 and 11 days were, respectively, needed to induce complete remission for the two responders, whereas in gout only a median of 5 days (3, 5, and 5 days, resp.) was needed. For the third patient with crowned dens syndrome, anakinra withdrawal on the 7th day in the context of marked reduction but persistent neck pains was followed by a rapid disease flare-up 48&#x2009;h later; the reintroduction of a second course of anakinra led to rapid, complete, and persistent remission of all acute clinical signs associated with CRP level normalization at the 11th day, allowing for withdrawing the treatment this same day. Finally, a median of 11 days (9, 11, and 11 days, resp.) was required for complete remission in crowned dens syndrome patients.</p>
        <p>Finally, a gouty patient (patient 6) exhibited a relapse six weeks after anakinra withdrawal. While the reintroduction of anakinra did not allow disease control at the 5th day, adjunction of colchicine led to persistent complete remission at the 3rd day of the combined treatment. For all six patients, after anakinra withdrawal, dietary recommendations associated with allopurinol, febuxostat, and/or colchicine were continued as prophylactic measures; no further relapse occurred within a follow-up of 6 to 16 months.</p>
      </sec>
      <sec id="sec3.3">
        <title>3.3. Treatment Safety</title>
        <p>Anakinra showed good or excellent tolerance profiles among all patients. Two patients (patients 1 and 4) had mild injection-site reactions and transient diffuse pruritus. No episodes of neutropenia or infection were observed. Despite initial decrease in renal function (creatinine clearance: 40&#x2013;20&#x2009;mL/min) in some patients, daily injections of anakinra were not harmful and even improved the renal parameters of patient 4 who probably had chronic gouty nephropathy. Colchicine tolerance was also good, although patients 2 and 4 presented episodic diarrhea. Finally, for patient 3 who had an ongoing staphylococcal soft-tissue infection, the use of anakinra rather than colchicine was harmless.</p>
      </sec>
    </sec>
    <sec id="sec4">
      <title>4. Discussion</title>
      <p>In the context of failure or contraindications to conventional therapies, anakinra exhibited good efficacy in all three types of CRIA with a longer treatment duration in crowned dens syndrome and associated peripheral arthritis related to pseudogout and/or HADD (9, 11, and 11 days, resp.) than in gouty arthritis (3, 5, and 5 days, resp.). Moreover, adjunction of colchicine to anakinra seems to allow a best outcome in CRIA refractory to each drug alone. To the best of our knowledge, this is the first report of anakinra use and efficacy for crowned dens syndrome related to pseudogout and HADD and also for HADD peripheral subacute arthritis. The tolerance in elderly patients was good in our series. Indeed, several articles showed that anti-IL-1 agents, such as anakinra, are safe in comparison with other biotherapies, such as anti-TNF-alpha, considering the risk of tuberculosis reactivation [<xref rid="B8" ref-type="bibr">9</xref>, <xref rid="B9" ref-type="bibr">10</xref>].</p>
      <p>Only few small series have been reported on the use of anakinra in gout and pseudogout as curative and/or prophylactic treatment. Molt&#xF3; et al. showed that, in four out of five patients suffering from refractory subacute oligo/polyarticular flare-ups of pseudogout, anakinra use for three days allowed dramatic clinical control and normalization of CRP as soon as the third day [<xref rid="B6" ref-type="bibr">6</xref>]. Announ et al. and McGonagle et al. showed similar results for anakinra, used as a curative or prophylactic treatment for recurrent subacute or chronic polyarticular pseudogout in two patients for at least 6 months [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B10" ref-type="bibr">11</xref>]. Although Couderc et al. reported three patients with a satisfactory result with anakinra to prevent acute flare-ups, this drug was unable to control chronic synovitis symptoms in two of them [<xref rid="B7" ref-type="bibr">7</xref>].</p>
      <p>Whereas gouty acute/subacute arthritis usually needed only three days of anakinra treatment, a longer treatment duration was necessary to control acute pseudogout flare-ups (14 days for the patient reported by McGonagle et al.) or chronic synovitis (i.e., at least three months), as observed for our patients and those in the literature [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. For two pseudogout polyarthritis patients, reported by Verhoeven et al., anakinra prescribed for five days showed no or only slight response [<xref rid="B11" ref-type="bibr">12</xref>]. These authors concluded that this poor efficacy of anakinra might be related to the systemic inflammation and/or to the long duration of this disease (2&#x2013;6 months); these data also correlate with those of Couderc et al. [<xref rid="B7" ref-type="bibr">7</xref>].</p>
      <p>Considering our pseudogout patients and those reported by others, this hypothesis appears only partially consistent. Treatment duration of five days leading to poor efficacy of anakinra in the series of Verhoeven et al. [<xref rid="B11" ref-type="bibr">12</xref>] was much shorter than the minimum of nine days in our series and for the patient reported by McGonagle et al. [<xref rid="B5" ref-type="bibr">5</xref>]. Thus, we hypothesize that treatment duration is the major factor in anakinra success to treat pseudogout and probably also HADD attacks. Indeed, in the pathophysiology of CRIA, the key role of IL-1 is now well documented: induction of IL-6 and TNF-alpha upregulation, complex retroinduction of other cytokines, leading to self-sustaining multicytokine vicious circle notably in cases of prolonged attacks [<xref rid="B12" ref-type="bibr">13</xref>&#x2013;<xref rid="B14" ref-type="bibr">15</xref>].</p>
      <p>Deposition of hydroxyapatite crystals in joints and periarticular tissues can cause acute attacks, qualified as pseudopodagra, which mimic gout and/or pseudogout attacks [<xref rid="B12" ref-type="bibr">13</xref>, <xref rid="B15" ref-type="bibr">16</xref>]. Paz&#xE1;r et al. have shown that, similar to MSU and CPP, hydroxyapatite crystals can also act as alarmins and trigger NLRP3 inflammasome activation [<xref rid="B12" ref-type="bibr">13</xref>]. The consequent overproduction of IL-1<italic>&#x3B2;</italic> seems indirectly mediated by increased levels of other proinflammatory stimuli, including TNF-<italic>&#x3B1;</italic> or uric acid [<xref rid="B16" ref-type="bibr">17</xref>, <xref rid="B17" ref-type="bibr">18</xref>]. Paz&#xE1;r et al. thus suggested that the IL-1 blockade may be clinically useful in acute HADD manifestations; this hypothesis was clinically confirmed for two of our patients [<xref rid="B12" ref-type="bibr">13</xref>]. Adding anakinra to previous ongoing treatments and, notably, colchicine should lead to the best response, as seen in the report of McGonagle et al. and for one of our polyarticular gouty patients [<xref rid="B5" ref-type="bibr">5</xref>].</p>
      <p>To conclude, IL-1 blockade seems to be an interesting therapeutic option for all three types of CRIA whatever the type of joint involvement, including the debilitating and often misdiagnosed crowned dens syndrome. As observed in this short series and in sparse literature data, acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis [<xref rid="B14" ref-type="bibr">15</xref>]. Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. Therefore, larger studies are needed to best assess the treatment modalities of anakinra in acute/subacute manifestations of the various types of CRIA, including its association with conventional drugs in curative and prophylactic purposes.</p>
    </sec>
  </body>
  <back>
    <sec sec-type="conflict">
      <title>Conflict of Interests</title>
      <p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>So</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>de Smedt</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Revaz</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tschopp</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>A pilot study of IL-1 inhibition by anakinra in acute gout</article-title>
          <source>
            <italic>Arthritis Research and Therapy</italic>
          </source>
          <year>2007</year>
          <volume>9</volume>
          <issue>2, article R28</issue>
          <pub-id pub-id-type="doi">10.1186/ar2143</pub-id>
          <pub-id pub-id-type="other">2-s2.0-34047174085</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cronstein</surname>
              <given-names>B. N.</given-names>
            </name>
            <name>
              <surname>Terkeltaub</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>The inflammatory process of gout and its treatment</article-title>
          <source>
            <italic>Arthritis Research &amp; Therapy</italic>
          </source>
          <year>2006</year>
          <volume>8</volume>
          <issue>supplement 1, article S3</issue>
          <pub-id pub-id-type="doi">10.1186/ar1908</pub-id>
          <pub-id pub-id-type="other">2-s2.0-33745254724</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martinon</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>P&#xE9;trilli</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Mayor</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Tardivel</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Tschopp</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Gout-associated uric acid crystals activate the NALP3 inflammasome</article-title>
          <source>
            <italic>Nature</italic>
          </source>
          <year>2006</year>
          <volume>440</volume>
          <issue>7081</issue>
          <fpage>237</fpage>
          <lpage>241</lpage>
          <pub-id pub-id-type="doi">10.1038/nature04516</pub-id>
          <pub-id pub-id-type="other">2-s2.0-32944468985</pub-id>
          <pub-id pub-id-type="pmid">16407889</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghosh</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rawat</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Simkin</surname>
              <given-names>P. A.</given-names>
            </name>
            <name>
              <surname>Gardner</surname>
              <given-names>G. C.</given-names>
            </name>
          </person-group>
          <article-title>Treatment of acute gouty arthritis in complex hospitalized patients with anakinra</article-title>
          <source>
            <italic>Arthritis Care and Research</italic>
          </source>
          <year>2013</year>
          <volume>65</volume>
          <issue>8</issue>
          <fpage>1381</fpage>
          <lpage>1384</lpage>
          <pub-id pub-id-type="other">2-s2.0-84881334136</pub-id>
          <pub-id pub-id-type="doi">10.1002/acr.21989</pub-id>
          <pub-id pub-id-type="pmid">23650178</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McGonagle</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>A. L.</given-names>
            </name>
            <name>
              <surname>Madden</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Emery</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>McDermott</surname>
              <given-names>M. F.</given-names>
            </name>
          </person-group>
          <article-title>Successful treatment of resistant pseudogout with anakinra</article-title>
          <source>
            <italic>Arthritis and Rheumatism</italic>
          </source>
          <year>2008</year>
          <volume>58</volume>
          <issue>2</issue>
          <fpage>631</fpage>
          <lpage>633</lpage>
          <pub-id pub-id-type="doi">10.1002/art.23119</pub-id>
          <pub-id pub-id-type="other">2-s2.0-39749175570</pub-id>
          <pub-id pub-id-type="pmid">18240249</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Molt&#xF3;</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ea</surname>
              <given-names>H.-K.</given-names>
            </name>
            <name>
              <surname>Richette</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bardin</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Liot&#xE9;</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis</article-title>
          <source>
            <italic>Joint Bone Spine</italic>
          </source>
          <year>2012</year>
          <volume>79</volume>
          <issue>6</issue>
          <fpage>621</fpage>
          <lpage>623</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jbspin.2012.01.010</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84870699350</pub-id>
          <pub-id pub-id-type="pmid">22658375</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Couderc</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mathieu</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Glace</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Soubrier</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of anakinra in articular chondrocalcinosis: report of three cases</article-title>
          <source>
            <italic>Joint Bone Spine</italic>
          </source>
          <year>2012</year>
          <volume>79</volume>
          <issue>3</issue>
          <fpage>330</fpage>
          <lpage>331</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jbspin.2011.12.017</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84860595927</pub-id>
          <pub-id pub-id-type="pmid">22341584</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wallace</surname>
              <given-names>S.-L.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Masi</surname>
              <given-names>A. T.</given-names>
            </name>
            <name>
              <surname>Decker</surname>
              <given-names>J. L.</given-names>
            </name>
            <name>
              <surname>McCarty</surname>
              <given-names>D. J.</given-names>
            </name>
            <name>
              <surname>Y&#xFC;</surname>
              <given-names>T. F.</given-names>
            </name>
          </person-group>
          <article-title>Preliminary criteria for the classification of the acute arthritis of primary gout</article-title>
          <source>
            <italic>Arthritis &amp; Rheumatism</italic>
          </source>
          <year>1977</year>
          <volume>20</volume>
          <issue>3</issue>
          <fpage>895</fpage>
          <lpage>900</lpage>
          <pub-id pub-id-type="doi">10.1002/art.1780200320</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0017483654</pub-id>
          <pub-id pub-id-type="pmid">856219</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cantarini</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Lopalco</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Caso</surname>
              <given-names>F.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh&#xE7;et's disease</article-title>
          <source>
            <italic>Autoimmunity Reviews</italic>
          </source>
          <year>2015</year>
          <volume>14</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1016/j.autrev.2014.08.008</pub-id>
          <pub-id pub-id-type="pmid">25151975</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Selmi</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ceribelli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Naguwa</surname>
              <given-names>S. M.</given-names>
            </name>
            <name>
              <surname>Cantarini</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Shoenfeld</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Safety issues and concerns of new immunomodulators in rheumatology</article-title>
          <source>
            <italic>Expert Opinion on Drug Safety</italic>
          </source>
          <year>2015</year>
          <volume>14</volume>
          <issue>3</issue>
          <fpage>389</fpage>
          <lpage>399</lpage>
          <pub-id pub-id-type="doi">10.1517/14740338.2015.993605</pub-id>
          <pub-id pub-id-type="pmid">25518908</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Announ</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Guerne</surname>
              <given-names>P. A.</given-names>
            </name>
            <name>
              <surname>Gabay</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure</article-title>
          <source>
            <italic>Joint Bone Spine</italic>
          </source>
          <year>2009</year>
          <volume>76</volume>
          <issue>4</issue>
          <fpage>424</fpage>
          <lpage>426</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jbspin.2009.01.001</pub-id>
          <pub-id pub-id-type="other">2-s2.0-67649798632</pub-id>
          <pub-id pub-id-type="pmid">19289295</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Verhoeven</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Prati</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Godfrin-Valnet</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Guillot</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Wendling</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>IL1 blockade in crystal-induced arthritis: impact of disease duration and the inflammatory syndrome. Comments on the article by Couderc M. et al. &#x2018;Efficacy of anakinra in articular chondrocalcinosis.&#x2019;</article-title>
          <source>
            <italic>Joint, Bone, Spine: Revue du Rhumatisme</italic>
          </source>
          <year>2013</year>
          <volume>80</volume>
          <issue>1</issue>
          <fpage>115</fpage>
          <lpage>116</lpage>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paz&#xE1;r</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Ea</surname>
              <given-names>H. K.</given-names>
            </name>
            <name>
              <surname>Narayan</surname>
              <given-names>S.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Basic calcium phosphate crystals induce monocyte/macrophage IL-1<italic>&#x3B2;</italic> secretion through the NLRP3 inflammasome in vitro</article-title>
          <source>
            <italic>Journal of Immunology</italic>
          </source>
          <year>2011</year>
          <volume>186</volume>
          <issue>4</issue>
          <fpage>2495</fpage>
          <lpage>2502</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.1001284</pub-id>
          <pub-id pub-id-type="other">2-s2.0-79951846190</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meng</surname>
              <given-names>Z. H.</given-names>
            </name>
            <name>
              <surname>Hudson</surname>
              <given-names>A. P.</given-names>
            </name>
            <name>
              <surname>Schumacher</surname>
              <given-names>H. R.</given-names>
              <suffix>Jr.</suffix>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>J. F.</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>D. G.</given-names>
            </name>
          </person-group>
          <article-title>Monosodium urate, hydroxyapatite, and calcium pyrophosphate crystals induce tumor necrosis factor-<italic>&#x3B1;</italic> expression in a mononuclear cell line</article-title>
          <source>
            <italic>The Journal of Rheumatology</italic>
          </source>
          <year>1997</year>
          <volume>24</volume>
          <issue>12</issue>
          <fpage>2385</fpage>
          <lpage>2388</lpage>
          <pub-id pub-id-type="other">2-s2.0-0031451596</pub-id>
          <pub-id pub-id-type="pmid">9415647</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lopalco</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Cantarini</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Vitale</surname>
              <given-names>A.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives</article-title>
          <source>
            <italic>Mediators of Inflammation</italic>
          </source>
          <year>2015</year>
          <volume>2015</volume>
          <fpage>21</fpage>
          <pub-id pub-id-type="publisher-id">194864</pub-id>
          <pub-id pub-id-type="doi">10.1155/2015/194864</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fam</surname>
              <given-names>A. G.</given-names>
            </name>
            <name>
              <surname>Rubenstein</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Hydroxyapatite pseudopodagra. A syndrome of young women</article-title>
          <source>
            <italic>Arthritis and Rheumatism</italic>
          </source>
          <year>1989</year>
          <volume>32</volume>
          <issue>6</issue>
          <fpage>741</fpage>
          <lpage>747</lpage>
          <pub-id pub-id-type="doi">10.1002/anr.1780320612</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0024411491</pub-id>
          <pub-id pub-id-type="pmid">2544186</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cantarini</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Lucherini</surname>
              <given-names>O. M.</given-names>
            </name>
            <name>
              <surname>Frediani</surname>
              <given-names>B.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes</article-title>
          <source>
            <italic>International Journal of Immunopathology and Pharmacology</italic>
          </source>
          <year>2011</year>
          <volume>24</volume>
          <issue>4</issue>
          <fpage>827</fpage>
          <lpage>836</lpage>
          <pub-id pub-id-type="other">2-s2.0-84856571891</pub-id>
          <pub-id pub-id-type="pmid">22230390</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rigante</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Lopalco</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Vitale</surname>
              <given-names>A.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Untangling the web of systemic autoinflammatory diseases</article-title>
          <source>
            <italic>Mediators of Inflammation</italic>
          </source>
          <year>2014</year>
          <volume>2014</volume>
          <fpage>15</fpage>
          <pub-id pub-id-type="publisher-id">948154</pub-id>
          <pub-id pub-id-type="doi">10.1155/2014/948154</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="fig1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Iconographic features of crowned dens syndrome and crystal-induced peripheral arthritis of patient 1 (a), patient 2 (b), and patient 3 (c(A) and c(B)). (a) Cervical CT-scan centered on the odontoid process: fine linear arciform calcification of the retroodontoid ligament suggesting pseudogout involvement. (b) Cervical CT-scan centered on odontoid process: cloudlike calcification of the retroodontoid ligament suggesting hydroxyapatite disease deposition involvement. (c(A)) Cervical CT-scan centered on odontoid process: thick arciform calcification of the retrodens ligament. (c(B)) Right shoulder MRI (T2 and T1): supraspinatus tendinopathy with partial rupture aspect. Tenosynovitis of the long biceps. Tendinopathy of the infraspinatus and subscapularis tendons.</p>
      </caption>
      <graphic xlink:href="MI2015-792173.001"/>
    </fig>
    <fig id="fig2" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Evolution of CRP levels on gouty polyarthritis patients (<italic>n</italic> = 3) and crowned dens patients associated with peripheral pseudogout or hydroxyapatite deposition disease patients (<italic>n</italic> = 3) arthritis under anakinra. Normalization of CRP levels at the 3rd or 5th days for the three polyarthritis gouty patients (grey and dotted lines) associated with complete clinical response and stopping anakinra. Same but later upcoming for two crowned dens syndrome patients (black continue lines), respectively, at the 9th or 11th days of treatment. For the 3rd crowned dens syndrome patient, early cessation of the treatment stopping within the 7&#x2013;9th days (hatched ellipse) showed reincrease of CRP levels; resuming of anakinra for 11 days showed complete and sustained control of CRP levels and clinical signs.</p>
      </caption>
      <graphic xlink:href="MI2015-792173.002"/>
    </fig>
    <table-wrap id="tab1" orientation="portrait" position="float">
      <label>Table 1</label>
      <caption>
        <p>Main clinical features and outcomes of patients displaying crystal-induced arthritis treated with anakinra.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" rowspan="2" colspan="1">Patients</th>
            <th align="center" colspan="3" rowspan="1">Crowned dens syndrome and associated peripheral crystal-induced arthritis</th>
            <th align="center" colspan="3" rowspan="1">Polyarticular gout</th>
          </tr>
          <tr>
            <th align="left" rowspan="1" colspan="1">Patient 1</th>
            <th align="left" rowspan="1" colspan="1">Patient 2</th>
            <th align="left" rowspan="1" colspan="1">Patient 3</th>
            <th align="left" rowspan="1" colspan="1">Patient 4</th>
            <th align="left" rowspan="1" colspan="1">Patient 5</th>
            <th align="left" rowspan="1" colspan="1">Patient 6</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" rowspan="1" colspan="1">Age/gender</td>
            <td align="left" rowspan="1" colspan="1">65/F</td>
            <td align="left" rowspan="1" colspan="1">88/F</td>
            <td align="left" rowspan="1" colspan="1">84/F</td>
            <td align="left" rowspan="1" colspan="1">66/M</td>
            <td align="left" rowspan="1" colspan="1">71/M</td>
            <td align="left" rowspan="1" colspan="1">72/F</td>
          </tr>
          <tr>
            <td align="center" colspan="7" rowspan="1">
<hr/>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Background condition</td>
            <td align="left" rowspan="1" colspan="1"> Pseudogout</td>
            <td align="left" rowspan="1" colspan="1">Hydroxyapatite deposition disease (HADD)</td>
            <td align="left" rowspan="1" colspan="1"> Pseudogout (associated with HADD iconographic picture)</td>
            <td align="left" rowspan="1" colspan="1">Gout with tophus</td>
            <td align="left" rowspan="1" colspan="1">Gout</td>
            <td align="left" rowspan="1" colspan="1">Gout</td>
          </tr>
          <tr>
            <td align="center" colspan="7" rowspan="1">
<hr/>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Comorbid conditions</td>
            <td align="left" rowspan="1" colspan="1">Hypothyroidism</td>
            <td align="left" rowspan="1" colspan="1">Essential arterial hypertension; hypothyroidism</td>
            <td align="left" rowspan="1" colspan="1">Suspected Horton disease, postsurgical staphylococcal infected ingrown nail</td>
            <td align="left" rowspan="1" colspan="1">Essential arterial hypertension; severe chronic renal insufficiency</td>
            <td align="left" rowspan="1" colspan="1">Diabetes; grade 4 neutropenia to colchicine; polycythemia vera treated with hydroxyurea and allopurinol</td>
            <td align="left" rowspan="1" colspan="1">Obesity; essential arterial hypertension; mild renal insufficiency; MGUS; allergy to allopurinol; prolymphocytic leukemia treated with pentostatin</td>
          </tr>
          <tr>
            <td align="center" colspan="7" rowspan="1">
<hr/>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Diagnosis</td>
            <td align="left" rowspan="1" colspan="1">Crowned dens syndrome<break/>Pseudorheumatoid arthritis </td>
            <td align="left" rowspan="1" colspan="1">Crowned dens syndrome<break/>Intra-articular acute HADD</td>
            <td align="left" rowspan="1" colspan="1">Crowned dens syndrome, temporomandibular and peripheral pseudogout and/or HADD oligoarthritis</td>
            <td align="left" rowspan="1" colspan="1">Subintrant articular gouty attacks<break/>Gouty nephropathy </td>
            <td align="left" rowspan="1" colspan="1">Subintrant articular gouty attacks</td>
            <td align="left" rowspan="1" colspan="1">Persistent articular gouty attacks</td>
          </tr>
          <tr>
            <td align="center" colspan="7" rowspan="1">
<hr/>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Acute joint involvement</td>
            <td align="left" rowspan="1" colspan="1">Periodontoid structures<break/>Symmetrical large and small joints</td>
            <td align="left" rowspan="1" colspan="1">Periodontoid structures<break/>Right shoulder<break/>Left wrist</td>
            <td align="left" rowspan="1" colspan="1">Periodontoid and left temporomandibular joint structures, right shoulder and left wrist</td>
            <td align="left" rowspan="1" colspan="1">Symmetrical large and small joints</td>
            <td align="left" rowspan="1" colspan="1">Large and small joints</td>
            <td align="left" rowspan="1" colspan="1">symmetrical large and small joints</td>
          </tr>
          <tr>
            <td align="center" colspan="7" rowspan="1">
<hr/>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Systemic signs (C reactive protein: CRP N &lt; 5&#x2009;mg/L)</td>
            <td align="left" rowspan="1" colspan="1">Fever <break/>Anorexia<break/>Marked inflammatory syndrome (CRP &#x2265; 90&#x2009;mg/L over 3 weeks)</td>
            <td align="left" rowspan="1" colspan="1">Alteration of the general state Fever<break/>Elevated inflammatory syndrome (CRP &#x2265; 60&#x2009;mg/L over 5 weeks)</td>
            <td align="left" rowspan="1" colspan="1">Fever<break/>Alteration of the general state<break/>Diffuse headaches <break/>Marked inflammatory syndrome (CRP &#x2265; 210&#x2009;mg/L over six weeks)</td>
            <td align="left" rowspan="1" colspan="1">Alteration of the general state<break/>Fever<break/>Elevated inflammatory syndrome (CRP &#x2265; 150&#x2009;mg/L over four weeks)<break/>Increase in creatininemia</td>
            <td align="left" rowspan="1" colspan="1">Febricula<break/>Alteration of the general state<break/>Persistent inflammatory syndrome (CRP &#x2265; 85&#x2009;mg/L over three weeks)</td>
            <td align="left" rowspan="1" colspan="1">Febricula<break/>Alteration of the general state<break/>Inflammatory syndrome <break/>(CRP &#x2265; 65&#x2009;mg/L over six weeks)</td>
          </tr>
          <tr>
            <td align="center" colspan="7" rowspan="1">
<hr/>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Indications for anakinra</td>
            <td align="left" rowspan="1" colspan="1">Failure of ketoprofen, then colchicine and associated oral cortisone</td>
            <td align="left" rowspan="1" colspan="1">Failure of colchicine and combined indomethacin, and oral cortisone</td>
            <td align="left" rowspan="1" colspan="1">Ongoing staphylococcal soft tissues infection treated with rifampicin and vancomycin leading to avoiding colchicine and high dose steroid drugs </td>
            <td align="left" rowspan="1" colspan="1">Failure of colchicine and associated oral cortisone</td>
            <td align="left" rowspan="1" colspan="1">Contraindication to colchicine<break/>Failure of cortisone and indomethacin</td>
            <td align="left" rowspan="1" colspan="1">Contraindication to allopurinol<break/>Failure of cortisone, indomethacin, and colchicine</td>
          </tr>
          <tr>
            <td align="center" colspan="7" rowspan="1">
<hr/>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Anakinra first treatment</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">&#x2003;Duration</td>
            <td align="left" rowspan="1" colspan="1">9 days</td>
            <td align="left" rowspan="1" colspan="1">7 days</td>
            <td align="left" rowspan="1" colspan="1">11 days</td>
            <td align="left" rowspan="1" colspan="1">5 days</td>
            <td align="left" rowspan="1" colspan="1">5 days</td>
            <td align="left" rowspan="1" colspan="1">3 days</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">&#x2003;Associated drugs</td>
            <td align="left" rowspan="1" colspan="1">None</td>
            <td align="left" rowspan="1" colspan="1">None</td>
            <td align="left" rowspan="1" colspan="1">Oral prednisone increased from 5 to 10&#x2009;mg/day</td>
            <td align="left" rowspan="1" colspan="1">None</td>
            <td align="left" rowspan="1" colspan="1">None</td>
            <td align="left" rowspan="1" colspan="1">None</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">&#x2003;Response</td>
            <td align="left" rowspan="1" colspan="1">Complete remission of all acute clinical and biological parameters</td>
            <td align="left" rowspan="1" colspan="1">Progressive improvement of clinical signs with slight cervical signs and normalization of CRP, allowing for consideration of complete response </td>
            <td align="left" rowspan="1" colspan="1">Dramatic and complete response on the wrist and temporomandibular joints, progressive complete response on the crowned dens syndrome and the wrist involvement, normalization of CRP levels on the 15th day</td>
            <td align="left" rowspan="1" colspan="1">Dramatic and complete remission of all acute clinical and biological parameters, and decrease in creatininemia</td>
            <td align="left" rowspan="1" colspan="1">Rapidand complete remission of all acute clinical and biological parameters</td>
            <td align="left" rowspan="1" colspan="1">Complete remission of all acute clinical signs, partial remission of biological parameters</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">&#x2003;Relapse or rebound</td>
            <td align="left" rowspan="1" colspan="1">None, under prophylactic treatment of colchicine </td>
            <td align="left" rowspan="1" colspan="1">Rebound 48&#x2009;h after improvement at anakinra withdrawal on the 7th day</td>
            <td align="left" rowspan="1" colspan="1">None, under prophylactic treatment with colchicine</td>
            <td align="left" rowspan="1" colspan="1">None, under prophylactic treatment with colchicine and allopurinol</td>
            <td align="left" rowspan="1" colspan="1">None,under prophylactic treatment with allopurinol</td>
            <td align="left" rowspan="1" colspan="1">Disease relapse 6 weeks after the initial complete response</td>
          </tr>
          <tr>
            <td align="center" colspan="7" rowspan="1">
<hr/>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Anakinra second treatment</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">&#x2003;Duration</td>
            <td align="left" rowspan="1" colspan="1">
NA</td>
            <td align="left" rowspan="1" colspan="1">11 days, until complete response</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">5 days</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">&#x2003;Associated drugs</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">None</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">None</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">&#x2003;Response</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">Dramatic complete remission of all acute clinical and biological parameters</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">Partial clinical and biological response</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">&#x2003;Relapse</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">None, with prophylactic treatment with colchicine</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
          </tr>
          <tr>
            <td align="center" colspan="7" rowspan="1">
<hr/>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Anakinra second treatment reintroduction</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
            <td align="left" rowspan="1" colspan="1">&#x2009;</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">&#x2003;Duration</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">3 days</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">&#x2003;Associated drugs</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">Colchicine</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">&#x2003;Response </td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">NA</td>
            <td align="left" rowspan="1" colspan="1">Complete clinical and biologic response, respectively, after 3 and 5 days of the combined treatment, respectively </td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
